From the Division of Plastic and Reconstructive Surgery, Stanford University; the Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center; the Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant' Andrea Hospital; the Division of Plastic and Reconstructive Surgery, University of Kentucky College of Medicine; the Division of Plastic and Reconstructive Surgery, Mayo Clinic; and the College of Health Sciences, University of Kentucky.
Plast Reconstr Surg. 2021 Jan 1;147(1):30e-41e. doi: 10.1097/PRS.0000000000007423.
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging and highly treatable cancer of the immune system that can form around textured-surface breast implants. Although the underlying cause has yet to be elucidated, an emerging theme-linking pathogenesis to a chronic inflammatory state-continues to dominate the current literature. Specifically, the combination of increasing mutation burden and chronic inflammation leads to aberrant T-cell clonal expansion. However, the impetus remains largely unknown. Proposed mechanisms include a lipopolysaccharide endotoxin response, oncogenic transformation related to viral infection, associated trauma to the breast pocket, particulate matter digestion by capsular macrophages, chronic allergic inflammation, and genetic susceptibility. The Janus kinase-signal transducer and activator of transcription 3 (JAK-STAT3) pathway is a major signaling pathway that regulates a variety of intracellular growth and survival processes. Constitutive activation of JAK-STAT3 has been implicated in several malignancies, including lymphomas, and has recently been identified as a potential key mediator in BIA-ALCL. The purpose of this article is to review the cellular and molecular mechanisms of BIA-ALCL with a focus on the role of oncogenic JAK-STAT3 signaling in BIA-ALCL tumorigenesis and progression. Selected experimental work from the authors' group on aberrant JAK-STAT3 signaling in BIA-ALCL is also included. The authors discuss how an inflammatory microenvironment may facilitate malignant transformation through the JAK-STAT3 pathway-highlighting its potential mechanistic role. The authors' hope is that further investigation of this signaling pathway will reveal avenues for using JAK-STAT3 signaling as a prognostic indicator and novel therapeutic target in the case of advanced disease.
乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)是一种新兴的、高度可治疗的免疫系统癌症,可在表面纹理乳房植入物周围形成。尽管其根本原因尚未阐明,但将发病机制与慢性炎症状态联系起来的一个新主题继续主导当前的文献。具体来说,增加的突变负担和慢性炎症的结合导致异常 T 细胞克隆扩增。然而,其推动力在很大程度上仍然未知。提出的机制包括脂多糖内毒素反应、与病毒感染相关的致癌转化、乳房口袋相关的创伤、囊状巨噬细胞消化颗粒物质、慢性过敏炎症和遗传易感性。Janus 激酶-信号转导和转录激活因子 3(JAK-STAT3)途径是调节各种细胞内生长和存活过程的主要信号通路。JAK-STAT3 的组成性激活与几种恶性肿瘤有关,包括淋巴瘤,最近被确定为 BIA-ALCL 的潜在关键介质。本文的目的是综述 BIA-ALCL 的细胞和分子机制,重点介绍致癌 JAK-STAT3 信号在 BIA-ALCL 肿瘤发生和进展中的作用。作者小组还包括关于 BIA-ALCL 中异常 JAK-STAT3 信号的选定实验工作。作者讨论了炎症微环境如何通过 JAK-STAT3 途径促进恶性转化,强调其潜在的机制作用。作者希望进一步研究该信号通路将揭示将 JAK-STAT3 信号用作先进疾病的预后指标和新的治疗靶点的途径。